Compare CELU & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELU | HOWL |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 30.7M |
| IPO Year | N/A | 2021 |
| Metric | CELU | HOWL |
|---|---|---|
| Price | $1.26 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | 101.9K | ★ 327.7K |
| Earning Date | 05-07-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.53 |
| 52 Week High | $4.35 | $2.23 |
| Indicator | CELU | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 53.89 |
| Support Level | $1.21 | $0.79 |
| Resistance Level | $1.33 | $0.90 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 39.62 | 38.00 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.